This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E76.1 | Special Copayment Reduction: V117 | Coverage period: 5 years |
| B. Synonyms | Mucopolysaccharidosis type II, Hunter syndrome |
| C. Adult onset | Likelihood of first onset in adulthood: very low — Symptoms begin at age 2–4, and the severe form leads to death at age 10–15; the mild non-neuronopathic form can survive into adulthood, but diagnosis is made in childhood |
| Section | Summary |
|---|---|
| 1. History | First described by Charles Hunter in 1917. IDS enzyme identified in 1978, IDS gene cloned in 1990. Idursulfase FDA-approved in 2006. |
| 2. Causes | Iduronate-2-sulfatase (I2S) deficiency due to IDS gene mutations. Intralysosomal accumulation of HS and DS. X-linked recessive inheritance, so mainly affects boys. |
| 3. Genetics | IDS gene located at Xq28 on the X chromosome. X-linked recessive inheritance. Over 660 variants reported. Large deletions and rearrangements associated with the severe form. |
| 4. General epidemiology | About 0.38–2.16 per 100,000 births (male births). Relatively high frequency in Japan (1/15,000). Disease in girls is extremely rare. |
| 5. Pathophysiology | I2S deficiency → blocked degradation of HS and DS → intralysosomal GAG accumulation → cellular dysfunction → multiorgan damage including the liver, spleen, heart, skeleton, and brain. |
| 6. Symptoms | Coarse facies, hepatosplenomegaly, joint contractures, hearing loss, recurrent respiratory infections. Cognitive regression in the severe form. Absence of corneal clouding distinguishes it from MPS I. |
| 7. Signs | Hepatosplenomegaly, ivory-colored papules of the skin, cardiac valve abnormalities, retinitis pigmentosa, hydrocephalus, airway obstruction findings. |
| 8. Screening | DBS-based I2S enzyme activity measurement, urinary GAG testing. Added to the US RUSP in 2022, with newborn screening expanding. |
| 9. Diagnosis | Measurement of leukocyte I2S enzyme activity is the gold standard. Confirmation by IDS gene analysis. IDS gene analysis is essential when a girl is affected. |
| 10. Treatment | Weekly intravenous ERT with idursulfase (Elaprase) is standard. HSCT has limited indications in the neuronopathic form. Intraventricular administration in clinical trials. |
| 11. Prognosis | Severe neuronopathic form: death at age 10–15. Mild non-neuronopathic form: survival into adulthood possible. Early ERT slows progression of physical symptoms. |
| 12. Prevention | Testing of carrier women and prenatal diagnosis, genetic counseling. Extended testing of maternal relatives such as maternal aunts and uncles recommended. |
| 13. References | 10 recent references (with PMID/DOI) |
Mucopolysaccharidosis type II (MPS II, Hunter syndrome) was first described in 1917 when Charles Hunter, a Canadian-born British physician, published in the British Medical Journal (BMJ) cases of two brothers with hepatosplenomegaly, dwarfism, intellectual disability, and cardiac abnormalities. Hunter also noted that the two brothers had an 'aggressive' temperament. Initially it was clinically similar to Hurler syndrome and difficult to distinguish, but from the 1940s the presence or absence of corneal clouding and the mode of inheritance (Hunter syndrome is X-linked recessive) were established as distinguishing points.
In the 1960s–70s, the mechanism of lysosomal enzyme deficiency began to be elucidated, and in 1978 Sjöberg et al. identified iduronate-2-sulfatase (I2S) as the deficient enzyme. In 1990, Wilson et al. cloned the IDS gene at Xq28 on the X chromosome, laying the foundation for molecular diagnosis. Since then, over 660 pathogenic variants have been reported, and it was confirmed that a partially duplicated pseudogene of IDS (IDS2) located nearby increases the frequency of rearrangements and deletions.
In the history of treatment, in 2006 idursulfase (Elaprase; Shire, now Takeda) received FDA and EMA approval and was introduced clinically as the first enzyme replacement therapy (ERT) for Hunter syndrome. Since then, treatment strategies targeting neurological pathology, such as intrathecal/intracerebroventricular ERT administration and gene therapy clinical trials, have been actively developed. In 2022, MPS II was added to the US Recommended Uniform Screening Panel (RUSP) for newborns, strengthening the early diagnosis system.
The direct cause of MPS II is deficiency or markedly reduced activity of the lysosomal enzyme iduronate-2-sulfatase (I2S). I2S is a sulfatase that removes sulfate groups during the degradation of heparan sulfate (HS) and dermatan sulfate (DS). When the enzyme is deficient, these two GAGs progressively accumulate within lysosomes, causing dysfunction of tissues throughout the body, including the liver, spleen, heart, bones, joints, respiratory tract, and central nervous system.
The causative gene, IDS, is located at Xq28 on the X chromosome, and because defects are inherited in an X-linked recessive manner, the disease mainly affects boys (hemizygotes). Girls are generally asymptomatic carriers with a pathogenic variant on only one of their two X chromosomes, but rarely the disease can also occur in girls in situations such as skewed X-inactivation or Turner syndrome (45,X).
The secondary pathological mechanisms due to GAG accumulation are similar to MPS I, with activation of intracellular inflammatory responses, oxidative stress, apoptosis, and disruption of growth factor signaling pathways acting in combination. Depending on whether the nervous system is involved, it is broadly divided into the neuronopathic (severe) and non-neuronopathic (mild) forms, which is a key classification criterion for determining prognosis and treatment strategy.
The IDS gene is located at position 28 of the long arm of the X chromosome (Xq28) and consists of 9 exons. The I2S protein is a lysosomal sulfatase composed of 550 amino acids and is activated after post-translational processing including glycosylation and formylglycine generation. A partially duplicated pseudogene called IDS2 is located near the IDS gene, so rearrangements (inversion, deletion) between IDS and IDS2 occur relatively often, usually causing a severe phenotype associated with complete loss of enzyme function.
To date, over 660 pathogenic variants have been reported in international registry studies such as the Human Gene Mutation Database (HGMD) and the Hunter Outcome Survey (HOS). Missense variants are the most common variant type, and nonsense variants, splicing variants, small insertions/deletions, and large deletions/rearrangements are included. Large IDS-IDS2 rearrangements are observed in about 13% of patients and are strongly associated with the severe neuronopathic form. Some missense variants preserve residual enzyme activity and are associated with a mild phenotype.
With X-linked recessive inheritance, the mothers of patients (hemizygous boys) are mostly carriers and generally asymptomatic. With each pregnancy, a carrier mother has a 50% chance of an affected son and a 50% chance of a carrier daughter. Rarely, a de novo mutation of the IDS gene occurs, and an affected child can be born without a family history. Germline mosaicism is also possible, so caution is needed in genetic counseling.
The worldwide birth prevalence of MPS II is reported as about 0.38–2.16 per 100,000 births, varying considerably by region and ethnicity. It is reported as about 1/73,000 in the United States and about 1/15,000 in Japan, with a relatively higher frequency observed in East Asia. Because it is X-linked recessive, almost all patients are boys, and female patients are extremely rare.
In Korea, accurate national prevalence data are lacking, but MPS II is a relatively frequently diagnosed form among MPS types in Korea. Worldwide, over about 2,000 patients are enrolled in the international registry (Hunter Outcome Survey, HOS). The ratio of the neuronopathic (severe) to non-neuronopathic (mild) form varies between reports, but the severe form is known to account for about 50–70%. In certain ethnic groups, a high frequency of particular variants is observed due to founder effects. With MPS II added to the US RUSP in 2022, newborn screening is expanding, and accumulation of more accurate prevalence data is expected as a result.
The core pathogenic mechanism of MPS II is progressive intralysosomal accumulation of HS and DS due to I2S enzyme deficiency. Normally, I2S removes the sulfate group from iduronate-2-sulfate residues at the nonreducing ends of HS and DS. When the enzyme is deficient, this degradation step is blocked and sulfated GAG chains accumulate in lysosomes. Accumulation occurs in tissues throughout the body, including the liver, spleen, cardiac valves, bones, joints, airways, and brain.
Secondary pathological mechanisms following GAG accumulation include lysosomal dysfunction, disruption of the autophagy pathway, mitochondrial dysfunction, activation of inflammatory mediators (cytokines, TLR4 signaling), and induction of apoptosis. In the nervous system, HS accumulation promotes neuronal death, glial cell activation, and neuroinflammation, causing progressive cognitive regression. In the cardiovascular system, GAG deposition in valvular interstitial cells causes valve thickening and dysfunction, and GAG may also deposit in the myocardium, causing cardiomyopathy. In the airways, GAG deposition in soft tissues causes upper airway narrowing and airway obstruction.
The difference between the neuronopathic (severe) and non-neuronopathic (mild) forms depends on the degree of GAG accumulation in the central nervous system and whether secondary neurotoxic mechanisms are activated. Current intravenous ERT does not sufficiently cross the blood-brain barrier and is limited in reducing the GAG burden in the nervous system, which is the main reason intraventricular administration or gene therapy is being studied in patients with the neuronopathic form.
MPS II patients are normal at birth, and symptoms begin to appear around age 2–4. Typical early symptoms are recurrent otitis media and upper respiratory infections, hernias (inguinal, umbilical), and abdominal distension due to hepatosplenomegaly. Developmental milestones in this period are normal or mildly delayed, but in the severe form rapid regression follows. The main symptoms are as follows:
Unlike MPS I, corneal clouding is absent or very mild, which is a clinical point of differentiation. In the severe (neuronopathic) form, cognitive regression begins around age 3–5 and is accompanied by behavioral problems such as hyperactivity, aggression, and sleep disturbances.
Characteristic physical examination findings are coarse facies, a short neck, and thoracolumbar kyphosis. In the eyes, the cornea is generally clear, which is a clinical point of differentiation from MPS I (Hurler syndrome). However, mild corneal clouding may be observed in some MPS II patients, and retinitis pigmentosa and optic atrophy may develop, so ophthalmologic examination is needed.
On the skin, ivory-colored nodular skin papules may be seen on the scapular region and lateral upper limbs, known as a relatively characteristic skin finding of MPS II. Hepatosplenomegaly is invariably found on abdominal examination. In the musculoskeletal system, finger contractures (claw hand), thoracolumbar kyphosis, oar-shaped deformity of the ribs, and femoral head dysplasia are observed.
A murmur may be heard on cardiac auscultation, and echocardiography shows thickening and regurgitation of the mitral, aortic, and tricuspid valves and myocardial hypertrophy. On neurological examination, patients with the severe form may show evidence of developmental regression, cervical nerve compression due to meningeal thickening, and findings of hydrocephalus. Brain MRI shows white matter abnormalities, ventricular enlargement, enlarged Virchow-Robin spaces, and parenchymal atrophy. Abdominal ultrasound shows hepatosplenomegaly and sometimes renal enlargement. Urinary GAG testing shows increased HS and DS, and audiometry shows conductive or mixed hearing loss.
Newborn screening for MPS II is important for early diagnosis and securing the optimal timing of treatment. With the addition of MPS II to the US Recommended Uniform Screening Panel (RUSP) in 2022, newborn screening is being expanded in the United States. Taiwan already performs newborn screening with a multi-enzyme panel including MPS II and is accumulating birth prevalence data.
As the main screening method, dried blood spot (DBS)-based measurement of I2S enzyme activity is most widely used. Iduronate-2-sulfatase activity is quantified using a fluorogenic substrate method or MS/MS, and samples with reduced activity proceed to confirmatory testing. Because MPS II is X-linked recessive, reduced enzyme activity is detected only in boys on newborn screening. A positive screen in a girl is likely to indicate a heterozygous carrier or a false positive.
Urinary GAG testing (qualitative, quantitative, and electrophoresis) is useful for first-line screening of clinically suspected patients. Because a pattern of increased HS and DS is common to MPS I and II, enzyme activity measurement and genetic analysis are always necessary for differentiation. In Korea, MPS II is not included in the national newborn screening items, but early diagnosis is possible through urinary GAG testing and enzyme activity measurement when there are clinically suspicious symptoms (coarse facies, recurrent hernias, hepatosplenomegaly, male).
MPS II is confirmed through I2S enzyme activity measurement and IDS gene analysis.
MPS II should be strongly suspected when findings such as coarse facies, hepatosplenomegaly, developmental delay/regression, recurrent respiratory infections, joint contractures, and characteristic skin papules appear in combination in a boy. Unlike MPS I, the absence of corneal clouding is an important point of differentiation. Because it is X-linked recessive, it is useful to check whether maternal relatives such as maternal uncles have a history of similar symptoms.
After confirming increased HS and DS by urinary GAG quantification (creatinine-corrected) and electrophoresis, I2S enzyme activity is measured in leukocytes or serum/plasma by a fluorogenic substrate method or LC-MS/MS. I2S activity below 10% of normal controls strongly suggests MPS II. However, the activity of other enzymes (sulfatases) that share substrates with I2S should also be checked at the same time to exclude multiple sulfatase deficiency.
Pathogenic variants are identified by sequencing all exons of the IDS gene (Sanger or NGS). Large deletions and rearrangements are confirmed by MLPA or aCGH. IDS-IDS2 rearrangements are confirmed by PCR-based specific testing. When reduced I2S activity is found in a girl, IDS gene analysis should determine whether she is a heterozygous carrier or, rarely, a hemizygous female patient. After diagnosis is confirmed, molecular genetic testing and genetic counseling are recommended for the carrier mother and sisters.
Treatment of MPS II combines disease-modifying treatment centered on ERT with multidisciplinary symptomatic treatment.
Idursulfase (Elaprase; Shire/Takeda) is a recombinant human I2S approved by the FDA and EMA in 2006. 0.5 mg/kg is administered intravenously once a week over about 3 hours. Clinical trials and long-term follow-up studies have demonstrated reduction in urinary GAG, improvement in hepatosplenomegaly, increase in 6-minute walk distance, and improvement in pulmonary function. However, because passage across the blood-brain barrier is limited, its effect on cognitive regression in patients with the neuronopathic form is limited. Hypersensitivity reactions may occur, so antihistamine premedication and monitoring are needed.
To reduce the GAG burden in the nervous system, clinical trials of intracerebroventricular or intrathecal I2S administration have been conducted. Idursulfase beta (Hunterase ICV) was approved in Korea in 2020 and is available as an intraventricular treatment option for pediatric patients with neuronopathic MPS II.
In MPS II, unlike in the Hurler form of MPS I, HSCT has not consistently been shown to suppress neurological regression, and considering the risk of transplant complications, it is generally not recommended on the current evidence base. Efficacy has been reported in certain patients with the mild non-neuronopathic form in some studies, but it has not yet been standardized.
This includes airway management (positive airway pressure for sleep apnea, tonsillectomy and adenoidectomy), regular cardiac monitoring and valve surgery, tympanostomy tube insertion, spinal fusion and decompression, carpal tunnel release, cerebrospinal fluid shunting, physical, occupational, and speech therapy, and behavioral management (treatment of hyperactivity and sleep disturbances in the neuronopathic form). Because the risk of surgical anesthesia is high, collaboration with an experienced anesthesiologist is essential.
Somatic gene therapy targeting the IDS gene (AAV vector-based) and gene-enhanced transplantation using hematopoietic stem cells (gene-enhanced HSCT) are at the clinical trial stage.
The prognosis of MPS II depends greatly on the presence of neuronopathy and whether treatment is given. In the severe neuronopathic form, cognitive regression progresses from around age 3–5, and most die from airway obstruction and cardiopulmonary failure before age 10–15. Idursulfase ERT is effective in improving physical symptoms (hepatosplenomegaly, walking ability, pulmonary function), but its main limitation is that, owing to limited passage across the blood-brain barrier, it does not significantly suppress cognitive regression.
In the mild non-neuronopathic form, cognitive function is preserved, and with appropriate ERT and symptomatic treatment, survival into adulthood is possible. Survival of some patients with the mild form into their 30s–50s or beyond has also been reported. However, physical complications such as progression of cardiac valve disease, airway obstruction, joint contractures, and carpal tunnel syndrome continue to accumulate, so ongoing multidisciplinary management is needed. Early diagnosis and early initiation of ERT are known to help slow the progression of physical symptoms.
Intraventricular ERT (idursulfase beta) has been reported to have some effect in maintaining cognitive function and suppressing progression of neurological symptoms in the neuronopathic form, but data on long-term efficacy are still accumulating. If gene therapy is applied clinically, improvement in the prognosis of the severe neuronopathic form is expected.
Because MPS II is an X-linked recessive genetic disease, prevention strategies must reflect the particular features of X-linked inheritance. Identifying carrier mothers is the key to prevention, which makes management of subsequent pregnancies and prenatal diagnosis possible.
In genetic counseling, carrier testing should be actively recommended for maternal female relatives, including the mother of a child with MPS II (maternal aunts, the mother's sisters, etc.). Because carrier women have no clinical symptoms, they can be identified only through molecular genetic testing (IDS gene analysis). Since it is difficult to identify carriers by enzyme activity alone, genetic testing is essential.
Prenatal diagnosis is made by measuring fetal I2S enzyme activity and IDS gene analysis through CVS at 10–12 weeks of gestation or amniocentesis at 15–18 weeks of gestation. Sex determination should come first (additional testing if the fetus is male). Preimplantation genetic testing (PGT-M) can be used in carrier mothers as a method of selecting and transferring normal embryos through IVF. The expanded introduction of newborn screening (listing on the US RUSP, multi-enzyme screening in Taiwan) contributes to secondary prevention through presymptomatic early diagnosis and early initiation of ERT.